Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis | Zendy

I-N. Park | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

Author(s) -

I-N. Park

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl298

Subject(s) - linezolid , medicine , tolerability , culture conversion , adverse effect , peripheral neuropathy , regimen , tuberculosis , surgery , sputum , vancomycin , pathology , staphylococcus aureus , endocrinology , biology , bacteria , genetics , diabetes mellitus

Although linezolid has good in vitro activity against Mycobacterium tuberculosis, its long-term use in the treatment of multidrug-resistant tuberculosis (MDR-TB) may be limited by its cost and serious adverse reactions. We therefore evaluated the efficacy and tolerability of a reduced dose of linezolid, in combination with other anti-TB drugs, in patients with intractable or extensive MDR-TB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research